| First Author | Zhu H | Year | 2016 |
| Journal | Genesis | Volume | 54 |
| Issue | 8 | Pages | 439-46 |
| PubMed ID | 27194399 | Mgi Jnum | J:236327 |
| Mgi Id | MGI:5805739 | Doi | 10.1002/dvg.22949 |
| Citation | Zhu H, et al. (2016) Cre-dependent DREADD (Designer Receptors Exclusively Activated by Designer Drugs) mice. Genesis 54(8):439-46 |
| abstractText | DREADDs, designer receptors exclusively activated by designer drugs, are engineered G protein-coupled receptors (GPCR) which can precisely control GPCR signaling pathways (for example, Gq, Gs, and Gi). This chemogenetic technology for control of GPCR signaling has been successfully applied in a variety of in vivo studies, including in mice, to remotely control GPCR signaling, for example, in neurons, glia cells, pancreatic beta-cells, or cancer cells. In order to fully explore the in vivo applications of the DREADD technology, we generated hM3Dq and hM4Di strains of mice which allow for Cre recombinase-mediated restricted expression of these pathway-selective DREADDs. With the many Cre driver lines now available, these DREADD lines will be applicable to studying a wide array of research and preclinical questions. genesis 54:439-446, 2016. (c) 2016 Wiley Periodicals, Inc. |
